Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany

Table 5 Results of the scenario analyses

Scenario	ΔQALY	ΔCosts	ICER
*Base case values*
- 5-grass tablet vs. allergoid mix	0.036	€ 458	€ 12,593
- 5-grass tablet vs. symptomatic tx	0.081	€ 1,385	€ 17,007
*Scenario analysis 1: 100% Lump sums*
- 5-grass tablet vs. allergoid mix	0.036	€ 546	€ 15,025
- 5-grass tablet vs. symptomatic tx	0.081	€ 1,362	€ 16,723
*Scenario analysis 2: 100% Public to private (ambulatory)*
- 5-grass tablet vs. allergoid mix	0.036	€ 305	€ 8,400
- 5-grass tablet vs. symptomatic tx	0.081	€ 1,414	€ 17,367
*Scenario analysis 3: Societal perspective*
- 5-grass tablet vs. allergoid mix	0.036	€ 339	€ 9,327
- 5-grass tablet vs. symptomatic tx	0.081	€ 784	€ 9,634
*Scenario analysis 4: Changing utilities*
- 5-grass tablet vs. allergoid mix	0.026	€ 458	€ 17,531
- 5-grass tablet vs. symptomatic tx	0.131	€ 1,385	€ 10,557
*Scenario analysis 5: Shorter pollen season*
- 5-grass tablet vs. allergoid mix	0.024	€ 266	€ 10,966
- 5-grass tablet vs. symptomatic tx	0.055	€ 1,198	€ 21,918

ISSN: 2045-7022